Bloomberg TalksBloomberg Talks

Novo Nordisk CEO Mike Doustdar Talks Drug Sales

View descriptionShare

Novo Nordisk has cut its forecast for the fourth time this year, after disappointing sales of its blockbuster drugs Wegovy and Ozempic. It underscores the challenges facing its new chief executive Mike Doustdar. He spoke to Bloomberg's Guy Johnson about the experience so far. 

 

 
  • Facebook
  • X (Twitter)
  • WhatsApp
  • Email
  • Download

In 1 playlist(s)

Bloomberg Talks

Listen for top interviews from Bloomberg News. Hear conversations with the biggest names in finance, 
Social links
Follow podcast
Recent clips
Browse 2,519 clip(s)